Drugs / MART-1
MART-1
Trials 11
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT01176461 | Aug 2010 → Dec 2016 | cutaneous melanoma | H. Lee Moffitt Cancer Center and Research Institute | Completed | No outcome recorded |
| Phase 1 | NCT00003792 | Apr 1999 → Oct 2006 | cutaneous melanoma | Baylor Health Care System | Completed | No outcome recorded |
| Phase 1/22 trials | ||||||
| Phase 1/2 | NCT01082198 | Oct 2002 → Apr 2010 | cutaneous melanoma | Maria Sklodowska-Curie National Research Institute of Oncology | Unknown | No outcome recorded |
| Phase 1/2 | NCT00019214 | Apr 1997 → Jul 2006 | cutaneous melanoma | National Cancer Institute (NCI) | Completed | No outcome recorded |
| Phase 26 trials | ||||||
| Phase 2 | NCT01307618 | Feb 2011 → Jan 2015 | melanoma | National Cancer Institute (NCI) | Terminated | No outcome recorded |
| Phase 2 | NCT00295958 | Dec 2005 → Jun 2006 | cutaneous melanoma | National Institutes of Health Clinical Center (CC) | Completed | No outcome recorded |
| Phase 2 | NCT00334776 | Oct 2003 → Jun 2005 | cutaneous melanoma, ocular melanoma | University of Southern California | Completed | No outcome recorded |
| Phase 2 | NCT00006385 | Sep 2000 → Oct 2006 | cutaneous melanoma | Eastern Cooperative Oncology Group | Completed | No outcome recorded |
| Phase 2 | NCT00006113 | Jun 1999 → May 2003 | cutaneous melanoma | University of Southern California | Terminated | No outcome recorded |
| Phase 2 | NCT00019396 | Feb 1998 → Mar 2007 | melanoma, renal cell carcinoma | National Cancer Institute (NCI) | Completed | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT00036816 | Feb 2002 → Feb 2003 | uveal melanoma | European Organisation for Research and Treatment of Cancer - EORTC | Terminated | No outcome recorded Stop: Enrollment |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 11 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | MART-1 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00036816 ↗ |
| Known as | HLA-A2-binding TYR/MART-1/gp100 multipeptide-pulsed autologous dendritic cell vaccine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01082198 ↗ |
| Action | Deplete | “Vaccines made from dendritic cells and tumor antigen peptides or a person's tumor cells may help the body build an effective immune response to kill tumor cells.” NCT01082198 ↗ |
| Modality | Peptide | “Melanoma peptides (MART-1:26-35, gp100:209-217, and tyrosinase:368-376)” NCT00006113 ↗ |
| Route | Intravenous | “vaccinations with dendritic cells pulsed with MART-1 and gp100 antigens, either intralymphatically every 4 weeks for 2 doses, or IV every 3 weeks for 4 doses” NCT00019214 ↗ |
| Route | Other | “vaccinations with dendritic cells pulsed with MART-1 and gp100 antigens, either intralymphatically every 4 weeks for 2 doses, or IV every 3 weeks for 4 doses” NCT00019214 ↗ |